* Results from 10-week analysis of phase 2 study with filgotinib in Crohn’s disease presented at ECCO Source text for Eikon: Further company coverage: (Gdynia Newsroom)
The post BRIEF-Galapagos presents filgotinib results at ECCO appeared first on NASDAQ.